ENCEPH UK Study
Start date:March 2015 End date:
December 2015 (Close to recruitment) Co-ordinated by:
Brain Infections UK, University of Liverpool Main trial site:
http://www.encephuk.org/studies
To produce a predictive tool for HSV encephalitis based on the early clinical features, by comparing the clinical features of those with and without HSV encephalitis.
Aim
To produce a predictive tool for HSV encephalitis based on the early clinical features, by comparing the clinical features of those with and without HSV encephalitis.
Trial Design
A Prospective multi-centre cohort observational study.
Eligibility criteria (summary of )
Patients who present to the Emergency Department or Acute Medical Unit with suspected encephalitis
Chief Investigator
Professor Tom Solomon
Local PI
Dr Matt Reed
Research Team
EMERGE Research team in collaboration with the Acute Medical Unit (AMU), Critical Care and the Virology team at the RIE
Further information
For more information please refer to main trial website
Local PI
Dr Matt Reed
Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine
Research Team
Polly Black
Senior Research Nurse
Julia Grahamslaw
Lead Research Nurse
More EMERGE Trials
Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.
NOVEL Study
Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions
People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.
Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.
KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.